PART 2 OF 4: Deal Breakers in Private Equity and MSO Transactions

Where investor capital meets the rules that govern medical practice.

Investor-backed transactions — private equity acquisitions, management services organization arrangements, and platform roll-ups — have reshaped healthcare, and they carry deal breakers all their own. These structures must reconcile investor capital with rules that were designed to keep medicine in the hands of clinicians. This article addresses the problems that most often derail investor-backed healthcare deals.

The Corporate Practice of Medicine barrier

The threshold problem in any investor-backed deal is that non-physicians cannot own a medical practice or control its clinical decisions. The entire transaction must be built around this constraint, typically through a management services organization structure. If the structure cannot be made to work — or if a proposed structure gives the investor too much control — the deal fails at its foundation.

The management fee and control problem

MSO arrangements live or die on their details. Two issues break these deals repeatedly:

• A management fee structured as a disguised split of professional profits, which can be treated as unlawful.

• An MSO that, in substance, controls clinical decisions the law reserves to physicians.

Loss of clinical autonomy

From the physician's side, a deal can break when the seller realizes how much autonomy the arrangement actually surrenders. Concerns over control of scheduling, staffing, clinical protocols, and the pace of care frequently surface late, and a seller who feels they are giving up more than they bargained for may walk away.

Compensation and alignment after the deal

Investor-backed deals often tie physician compensation to future performance through earn-outs, equity rollovers, and continued employment. These can break the deal when the parties cannot align on how physicians are paid going forward, how much they must reinvest, and how long they are locked in. Misalignment on post-closing economics is a frequent point of collapse.

Regulatory scrutiny of consolidation

Investor-backed healthcare transactions face growing regulatory attention, including state-level notice and review of certain healthcare deals. A transaction that triggers regulatory review, or that raises concerns about consolidation, can be delayed or blocked — a category of deal breaker that has become more prominent and warrants early analysis.

How West Coast Health Law Can Help

We advise physicians and investors on private equity and MSO transactions — structuring arrangements that comply with the Corporate Practice of Medicine doctrine, protect clinical autonomy, and withstand regulatory scrutiny.

West Coast Health Law offers a FREE consultation which you may schedule by clicking the button on our website.

This article is provided for general informational purposes only and does not constitute legal advice or create an attorney-client relationship. Laws change and every transaction is different; consult a qualified attorney about your specific situation.